| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 50.0% (1/2) | 0.0% (0/1) | -1.6% | -1.6% | -1.6% |
| 20D | 0No data | 0.0% (0/1) | — | — | — | — |
| 60D | 0No data | 0.0% (0/1) | — | — | — | — |
| 120D | 0No data | 0.0% (0/1) | — | — | — | — |
COMPANY RESEARCH
Coiled Therapeutics plc
COIL.L · United Kingdom · Healthcare · Biotechnology
INSIDER SIGNAL
Insider activity score：47.6 / 100
1 insiders · 1 purchase events · €47k net purchases
Europe #734 · United Kingdom #195
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+10.5 / 35
How many distinct insiders bought in the cluster
Purchase size+17.4 / 25
Purchase value relative to company size and liquidity
Role+13.0 / 20
The seniority and relevance of participating insiders
Recency+2.7 / 10
How recently the purchases occurred
Conviction+10.0 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Buyer breadth is moderate · fewer than 4 distinct filers
- ⚠ Insider role contributes less on the current role scale
- ⚠ Purchase activity is becoming less recent
The role contribution uses the inverted role input of the current European model.
Buying concentration
100%
Largest buyer：Stephen West · 40k GBP
Gross qualified purchase transaction-line value：40k GBP
The headline € total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| Stephen West | 0.07399–0.0765 GBP | Sep 28, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 1 distinct reported filers
- Peak time window
- 2026-09-28 to 2026-09-28
- Current breadth input
- 0.300 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Recent eligible purchase
Stephen West · 40k GBP · Price 0.07399–0.0765 GBP · Sep 28, 2026 - 🔴 1 other transaction line(s) are not counted as discretionary-buying evidence; 0 have zero price
Insider vs stock price
1 purchase day(s), 2 purchase line(s) in the 180-day window.
Daily close (GBp)Day with an insider purchase
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-09-28 | 1 | 817 −18.3% | 995 −0.5% | −178 −17.8 pts |
0 of 1 disclosure day(s) ended ahead of the median peer stock.
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (190 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
One insider bought, once (28 Sep). The share closed at 7.50 that day and at 6.12 most recently (−18.3%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
Blue line: this share's price, −25.8% over these six months
The closing price of each day, from 8.25 on 2026-04-21 to 6.12 on 2026-10-09. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, +2.5%
Taken from the 491 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −25.8%, the typical one +2.5%, 28.3 points behind. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases.
This company: insiders buying per month, last 12 months
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
1Sep
Oct
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| Stephen West | Board member | 1 | — | 40.0k GBP | 2026-09-28 | −18.3% | fewer than 5 completed |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.300 | 10.5 |
| Qualified-buy size | 25% | 0.698 | 17.4 |
| Role informativeness (inverted) | 20% | 0.350 | 7.0 |
| Recency | 10% | 0.268 | 2.7 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-10-13: no longer on the bull side: large purchases; no longer on the bear side: thinly traded. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
The purchases themselves carry no bull line, and share price and trading argue against (price down over six months, price trails its sector). No data is held for: company results.
- The insider purchases themselvesBearone buyer only5 checked, under the threshold · 3 missing
- Share price and tradingBearprice down over six months, price trails its sector
- Short sellers1 checked, under the threshold
- Company results2 missing
- Company actions1 checked, under the threshold
Bull case · the buying is informative
Nothing held here goes beyond the fact that an insider bought.
Bear case · discount it
- Only one insider bought. A single purchase can reflect that person's own finances rather than a view on the company.Record: after 4,732 earlier disclosures like this, the median 60-session excess return was −2.7%, within 1 percentage point of all comparable disclosures (−3.3%).
- Share price and tradingThe share price is down 28% over six months (three months −39%, one month −28%) and stands 80% below its 52-week high. Insiders have bought into a fall the market has not reversed.Record (nearest stored case: price 20% or more below its prior 52-week high): after 11,077 earlier disclosures like this, the median 60-session excess return was −3.2%, within 1 percentage point of all comparable disclosures (−2.6%).
- Share price and tradingOver three months the share price changed −39% and the median of 271 Healthcare companies changed −6.3%: 32 points behind. The market has marked this company down against its own sector.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- The company's market value is not captured, so the purchases cannot be stated as a share of the business or of its trading volume.
- No earnings, margin or cash-flow figures are captured for this company. The latest annual and interim reports are where to check whether the business is improving or deteriorating.
- European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. None of the 2 purchase lines mentions a plan, but a bare “Purchase of 531,743 Ordinary Shares” does not rule one out.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 7
- Either1 insider bought in the last 180 days and 0 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
- Bear0 of 1 buyer filed as a person closely associated with a manager. Counted for the bear side from half.
- EitherNet purchases of €47k in 180 days. Bull from €1.0M, bear when all purchases total under €25k.
- BearNo insider sale is recorded in the same 180 days.
- EitherThe latest purchase is 19 days old. Bull up to 14 days, bear from 90.
- BearThe register of FCA shows no published net short position in this company.
- BullThe company announced no transaction in its own shares in the last 30 days.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
47.6 / 100
Latest recorded score
↓ -7.3 ptssince the first recorded snapshot on 2026-09-28; 20 calendar days observed
- Recorded snapshots
- 18
- First snapshot
- 2026-09-28
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 54.9
- 52.5
- 50.7
- 48.5
- 47.6
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-09-28 | 54.9 |
| 2026-09-29 | 54.3 |
| 2026-09-30 | 53.6 |
| 2026-10-01 | 53.1 |
| 2026-10-02 | 52.5 |
| 2026-10-03 | 52.5 |
| 2026-10-04 | 52.5 |
| 2026-10-05 | 51.1 |
| 2026-10-06 | 50.7 |
| 2026-10-07 | 50.3 |
| 2026-10-08 | 49.9 |
| 2026-10-09 | 49.6 |
| 2026-10-12 | 48.7 |
| 2026-10-13 | 48.5 |
| 2026-10-14 | 48.2 |
| 2026-10-15 | 48.0 |
| 2026-10-16 | 47.8 |
| 2026-10-18 | 47.6 |
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #11 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (6d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 575.2%
- Beta
- —
- Avg daily volume
- £8,542.9
VALUATION
- Market cap
- —
- P/E
- —
FUNDAMENTALS
- Profit margin
- —
- ROE
- -19.9%
- Industry
- —
Prices to 11 Oct 2026: OpenBB/yfinance; volume from price cache (yfinance). From the company's annual report ↗, fiscal year ended 31 Dec 2024: ROE. It does not affect the insider score or rank.
Disclosed net short positions
The FCA register, read 18 Oct 2026, publishes no aggregate net short position for this issuer.
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Insiders' buying price vs the latest close
The latest close in the price history is more than a week old.
Buying size vs market trading
Market history is too old for this snapshot; ratios are withheld.
Market-data coverage: 507 verified sessions · Latest session: 2026-10-09 · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Latest news
No news has been captured for this company.
Regulatory filings
- Insider filing announcement · published 2026-09-28 · trade date 2026-09-28
- Insider filing announcement · published 2026-06-17 · trade date 2026-06-17
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
2 qualifying purchase disclosure(s) · 2 transaction line(s)
Sep 28, 2026Purchase of 531,743 Ordinary Shares
Stephen West · Non-Executive Director
Ordinary shares of £0.01 par value ISIN: GB00BSHRN331 · 270306 shares × 0.07399 GBP · —
Open filingSep 28, 2026Purchase of 531,743 Ordinary Shares
Stephen West · Non-Executive Director
Ordinary shares of £0.01 par value ISIN: GB00BSHRN331 · 261437 shares × 0.0765 GBP · —
Open filingShowing 2 of 2 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 1 other transaction(s)
Jun 17, 2026Grant of Options
1) Dr Andrew Dean 2) Robbin Frnka · 1) Non-Executive Director 2) Chief Clinical Operations
Identification code: · — shares × — · —
Open filingShowing 1 of 1 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- COIL.L
- ISIN
- GB00BSHRN331
- Sector
- Healthcare
- Industry
- Biotechnology
Company logos by Parqet